Wockhardt Limited has received an ESG rating of 65 (Aspiring) from NSE Sustainability Ratings and Analytics Limited for the year 2025. The pharmaceutical company disclosed this development through a regulatory filing dated 19th February, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

ESG Rating Breakdown

The overall ESG score of 65 reflects a comprehensive assessment across three key sustainability parameters. NSE Sustainability Ratings and Analytics Limited, a SEBI-registered ESG rating provider, conducted this evaluation as part of its voluntary ESG assessment process.

Independent Assessment Process

Wockhardt clarified that the company did not engage NSE Sustainability Ratings and Analytics Limited for this rating purpose. The assessment was conducted independently by the rating agency, utilizing the company's public disclosures and other publicly available information. This voluntary rating process demonstrates the growing emphasis on ESG evaluation in the Indian corporate landscape.

Company's ESG Commitment

According to the regulatory filing, the rating scores underscore Wockhardt's strong ESG commitment with steady progress and solid disclosures. The Governance parameter received the highest score at 74, followed by Social at 70, while Environmental scored 51. The company has made this information available on its official website at www.wockhardt.com for stakeholder reference.

Regulatory Compliance

The disclosure was made in compliance with SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024, which mandates listed companies to inform stock exchanges about ESG ratings received from SEBI-registered providers. This regulatory framework ensures transparency in ESG reporting and helps investors make informed decisions based on sustainability metrics.

Wockhardt Limited announced its Q3FY26 financial results on February 10, 2026, demonstrating robust performance across key metrics. The pharmaceutical company reported consolidated revenue of Rs 888 crores for the quarter ended December 31, 2025, representing a 23% year-over-year growth from Rs 721 crores in Q3FY24. Net profit after tax surged to Rs 61 crores compared to Rs 20 crores in the corresponding quarter of the previous year.

Consolidated Financial Performance

The company's consolidated results showed strong momentum across all major parameters. Total income reached Rs 913 crores, up from Rs 729 crores in Q3FY24, driven primarily by operational revenue growth.

Standalone Results Show Impressive Turnaround

On a standalone basis, Wockhardt demonstrated even stronger performance with revenue from operations reaching Rs 430 crores in Q3FY26, up 32% from Rs 325 crores in Q3FY24. The company achieved a net profit of Rs 28 crores compared to a loss of Rs 22 crores in the same quarter last year.

Nine-Month Performance Analysis

For the nine months ended December 31, 2025, consolidated revenue reached Rs 2,408 crores compared to Rs 2,269 crores in the corresponding period of FY24. The company reported net profit of Rs 35 crores for the nine-month period, a significant improvement from the loss of Rs 12 crores in the previous year.

Exceptional Items and Strategic Decisions

The company reported exceptional charges of Rs 107 crores for the nine-month period, primarily due to the exit from US generic pharmaceutical business. Wockhardt filed for voluntary liquidation of its US subsidiaries Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC under Chapter 7 of the US Bankruptcy Code on July 11, 2025. Additionally, the company accounted for Rs 10 crores as exceptional items related to the impact of India's new Labour Codes.

Board Meeting and Audit Compliance

The Board of Directors approved the unaudited financial results at their meeting held on February 10, 2026, which commenced at 11:45 a.m. and concluded at 02:15 p.m. The results were reviewed by the Audit Committee and subjected to limited review by M S K C & Associates LLP, the company's statutory auditors.

Source: Wockhardt Limited Q3FY26 Results